LumiThera receives $2.5 million grant to study dry AMD treatment option

LumiThera has received a $2.5 million small business innovative research phase II grant from the National Institute of Health and the National Eye Institute to continue research into its photobiomodulation treatment for dry age-related macular degeneration, according to a press release.

The funding will be used to support LIGHTSITE III, a prospective, randomized, multicenter human clinical trial that will test vision and examine disease pathology in dry AMD patients following photobiomodulation treatments using LumiThera’s Valeda light delivery system.

“We are excited to have the NIH/NEI partially support the further development endeavors of LumiThera, and the grant is a significant step in the validation of the PBM technology and its potential in treating chronic eye disease,” LumiThera President and CEO Clark Tedford, PhD, said in the release.

The Valeda light delivery system has received a CE mark for commercialization in Europe.

LumiThera has received a $2.5 million small business innovative research phase II grant from the National Institute of Health and the National Eye Institute to continue research into its photobiomodulation treatment for dry age-related macular degeneration, according to a press release.

The funding will be used to support LIGHTSITE III, a prospective, randomized, multicenter human clinical trial that will test vision and examine disease pathology in dry AMD patients following photobiomodulation treatments using LumiThera’s Valeda light delivery system.

“We are excited to have the NIH/NEI partially support the further development endeavors of LumiThera, and the grant is a significant step in the validation of the PBM technology and its potential in treating chronic eye disease,” LumiThera President and CEO Clark Tedford, PhD, said in the release.

The Valeda light delivery system has received a CE mark for commercialization in Europe.